2022 ASH Annual Meeting & Exposition - Focus on GVHD

The 64th American Society of Hematology Annual Meeting and Exposition took place December 10-13 in New Orleans, Louisiana. This year’s meeting featured plenary lectures, expert sessions, poster presentations, and much more. Find highlights from the sessions that are most relevant to oncology nurses, including those with a focus on the latest treatment strategies for graft-versus-host disease.

Does Belumosudil Affect Pharmacokinetics of Tacrolimus/Sirolimus in Patients With cGVHD?
The novel therapeutic belumosudil (BEL) was recently approved for use in patients with chronic graft-versus-host disease (cGVHD). Researchers at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, set out to determine whether BEL could affect the therapeutic levels of the current standard prophylaxis for cGVHD, tacrolimus (TAC) and sirolimus (SIRO), either in combination with one another or alone. ...
Advertisement
Dustin SamplesConferences | December 28, 2022
GVHD prophylaxis with itacitinib plus tacrolimus/sirolimus was safe and well-tolerated after transplant.
Read More
Dustin SamplesConferences | December 28, 2022
No GVHD was reported in patients with CD30-positive lymphoma who received CD30.CAR EBVSTs.
Dustin SamplesConferences | December 28, 2022
GVHD prophylaxis with posttransplant cyclophosphamide plus tacrolimus was better than tacrolimus alone for allogeneic HCT.
Cecilia BrownConferences | December 28, 2022
Extensive chronic GVHD occurred in 15% of patients with ALL within 2 years of undergoing allogeneic HSCT.
Cecilia BrownConferences | December 28, 2022
Patients receiving allogeneic HSCT face an average of $1 million in transplant-related costs throughout their lifetimes.
Cecilia BrownConferences | December 28, 2022
Belumosudil combination therapy in a real-world setting “appears safe, tolerable, and effective” for chronic GVHD.
Cecilia BrownConferences | December 28, 2022
Fludarabine plus busulfan led to lower rates of grade III-IV acute GVHD than cyclophosphamide plus busulfan.
Cecilia BrownConferences | December 28, 2022
No moderate-to-severe chronic GVHD occurred in patients with high-risk hematologic malignancies who received Orca-Q.
Cecilia BrownConferences | December 28, 2022
Around one-third of patients with TP53-mutated acute leukemias or MDS who underwent HSCT developed chronic GVHD.
Cecilia BrownConferences | December 28, 2022
Donor-derived, CD7-directed, CAR T-cell therapy had “encouraging activity” but led to reversible GVHD in 40% of patients.
Cecilia BrownConferences | December 28, 2022
No GVHD exacerbations occurred with a BCMA-directed CAR-T in patients with multiple myeloma.
Cecilia BrownConferences | December 28, 2022
Frailty is strongly associated with worse survival outcomes in patients with chronic graft-versus-host disease (GVHD).
Cecilia BrownConferences | December 28, 2022
No graft-versus-host disease (GVHD) occurred in patients with multiple myeloma (MM) who received allogeneic CAR-T therapy.
Dustin SamplesConferences | December 28, 2022
Donor age and type can significantly affect the outcomes of patients who undergo hematopoietic cell transplantation.
Cecilia BrownConferences | December 28, 2022
Around 25% of patients with high-risk MDS or AML who received venetoclax plus azacitidine maintenance developed chronic GVHD.
Dustin SamplesConferences | December 28, 2022
Belumosudil can impact the pharmacokinetics of tacrolimus and sirolimus, which is important for dosing considerations.
Dustin SamplesConferences | December 28, 2022
GVHD was only reported in one patient who received veto cells plus haploidentical T-cell-depleted HSCT.
Dustin SamplesConferences | December 28, 2022
Patients who received a triplet regimen as GVHD prophylaxis after HSCT had favorable outcomes.
Dustin SamplesConferences | December 28, 2022
A new method of peripheral blood stem cell hematopoietic cell transplantation led to a 1-year chronic GVHD rate of 11%.
Advertisement
Advertisement
Advertisement